GlaxoSmithKline: Breast Neoplasms trials
The registry lists 59 Breast Neoplasms studies with GlaxoSmithKline as lead sponsor. 1 are open to participants now and 27 have results posted.
Phase 1 20Phase 2 28Phase 3 6No phase 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyRecruitingNCT04641247Phase 2
- Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular DiseaseActive, not recruitingNCT04915755Phase 3Results posted
- Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With PembrolizumabCompletedNCT03674567Phase 1/2Results posted
- Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast CancerCompletedNCT03329937Phase 1Results posted
- Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast CancerTerminatedNCT02964507Phase 1Results posted
- Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian CancerCompletedNCT02657889Phase 1/2Results posted
- A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer PatientsTerminatedNCT01905592Phase 3Results posted
- Cancer in Patients With Gabapentin (GPRD)CompletedNCT01236053Results posted
- Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast CancerTerminatedNCT01220128Phase 2Results posted
- Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBCCompletedNCT01138046Phase 2Results posted
- Lapatinib in Combination With VinorelbineCompletedNCT01128543Phase 2Results posted
- Treatment With Pazopanib for Neoadjuvant Breast CancerCompletedNCT00849472Phase 2Results posted
- Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer SubjectsTerminatedNCT00709618Phase 2Results posted
- Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast CancerCompletedNCT00558103Phase 2Results posted
- Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.CompletedNCT00524303Phase 2Results posted
- Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast CancerTerminatedNCT00479856Phase 2Results posted
- Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast CancerCompletedNCT00477464Phase 2Results posted
- Brain Metastases In ErbB2-Positive Breast CancerTerminatedNCT00437073Phase 2Results posted
- Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast CancerCompletedNCT00429299Phase 2Results posted
- Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast CancerCompletedNCT00422903Phase 2Results posted
- Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast CancerCompletedNCT00374322Phase 3Results posted
- Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast CancerCompletedNCT00356811Phase 2Results posted
- Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast CancerCompletedNCT00347919Phase 2Results posted
- GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast CancerCompletedNCT00320411Phase 2Results posted
- Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast CancerCompletedNCT00320385Phase 3Results posted
- Lapatinib In Chemotherapy-Naive Or Metastatic Breast CancerCompletedNCT00089999Phase 2Results posted
- Study Of Ispinesib In Subjects With Breast CancerCompletedNCT00089973Phase 2Results posted
- Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast CancerCompletedNCT00075270Phase 3Results posted
- First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruitingNCT05277051Phase 1
- Patient-Reported Outcome Measurement Information System (PROMIS) Physical FunctionCompletedNCT03351140
- Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer PatientsCompletedNCT01782651
- Evaluation of Specific Biomarkers in Primary Invasive Breast CancerTerminatedNCT01476111
- Physician Liver Function Test (LFT) Monitoring for Tykerb PtsCompletedNCT01462552
- Role of Early Versus Late Switch to Lapatinib-CapecitabineTerminatedNCT01357863
- Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast CancerWithdrawnNCT01205217Phase 2
- A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast CancerWithdrawnNCT01137994Phase 2
- Brain Metastasis in Breast Cancer PatientsCompletedNCT01077648
- A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of LapatinibCompletedNCT00996762Phase 1
- A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795CompletedNCT00920257Phase 1
- A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast CancerCompletedNCT00849329Phase 1
- A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer PatientsCompletedNCT00821054Phase 1
- Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor CellsTerminatedNCT00820924Phase 2
- A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid TumorsCompletedNCT00722293Phase 1
- Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast CancerCompletedNCT00650910Phase 1
- Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast CancerWithdrawnNCT00615524Phase 2
- GW572016 In Patients With Advanced Or Metastatic Breast CancerCompletedNCT00462956Phase 1
- Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)CompletedNCT00388076Phase 1
- GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast CancerCompletedNCT00371488Phase 1
- Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast CancerCompletedNCT00359190Phase 1
- To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer PatientsCompletedNCT00258050Phase 1
- Rollover Study Of Lapatinib In Cancer PatientsCompletedNCT00169533Phase 1
- Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)CompletedNCT00148902Phase 1
- Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast CancerCompletedNCT00140738Phase 1
- Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast CancerCompletedNCT00111787Phase 2
- Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast CancerCompletedNCT00105950Phase 2
- Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast CancerCompletedNCT00078572Phase 3
- GW572016 For Treatment Of Refractory Metastatic Breast CancerCompletedNCT00062686Phase 2
- A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast CancerCompletedNCT00058526Phase 1
- Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.CompletedNCT00051103Phase 2